Pulmonx Corp [LUNG] stock is trading at $2.01, down -6.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LUNG shares have gain 24.07% over the last week, with a monthly amount glided 18.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pulmonx Corp [NASDAQ: LUNG] stock has seen the most recent analyst activity on July 31, 2025, when Piper Sandler downgraded its rating to a Neutral but kept the price target unchanged to $2.50 for it. Previously, D. Boral Capital started tracking the stock with Buy rating on March 10, 2025, and set its price target to $17. On December 11, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $7.50 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $12 on June 04, 2024. Wells Fargo downgraded its rating to a Equal Weight and reduced its price target to $14 on February 23, 2024. Craig Hallum started tracking with a Buy rating for this stock on September 05, 2023, and assigned it a price target of $18. In a note dated February 27, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $10 to $15.
Pulmonx Corp [LUNG] stock has fluctuated between $1.31 and $9.37 over the past year. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Pulmonx Corp [NASDAQ: LUNG] shares were valued at $2.01 at the most recent close of the market. An investor can expect a potential return of 61.69% based on the average LUNG price forecast.
Analyzing the LUNG fundamentals
Pulmonx Corp [NASDAQ:LUNG] reported sales of 91.66M for the trailing twelve months, which represents a growth of 5.47%. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -0.65%, Pretax Profit Margin comes in at -0.62%, and Net Profit Margin reading is -0.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.7 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.82.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.95 points at the first support level, and at 1.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.12, and for the 2nd resistance point, it is at 2.23.
Ratios To Look Out For
For context, Pulmonx Corp’s Current Ratio is 4.86. Also, the Quick Ratio is 4.15, while the Cash Ratio stands at 3.36. Considering the valuation of this stock, the price to sales ratio is 0.90, the price to book ratio is 1.38.
Transactions by insiders
Recent insider trading involved French Glendon E. III, President and CEO, that happened on Dec 01 ’25 when 8805.0 shares were sold. CHIEF COMMERCIAL OFFICER, Rose Geoffrey Beran completed a deal on Dec 01 ’25 to sell 6322.0 shares. Meanwhile, GENERAL COUNSEL Lehman David Aaron sold 10278.0 shares on Dec 01 ’25.
